Spyre Therapeutics Reports Q3 GAAP EPS of -$0.94, Missing Estimates by $0.11
Spyre Therapeutics (SYRE) reported third-quarter GAAP earnings per share of -$0.94, falling short of analyst expectations by $0.11. The miss highlights the ongoing capital requirements and operational costs typical for clinical-stage biotechnology firms. Despite the earnings miss, market interest remains focused on the company's pipeline development, specifically regarding SPY072 and potential combination therapies. Recent corporate activity includes a significant $350 million public offering priced at $85 per share to bolster its liquidity position.
Tickers: $SYRE
Topics: capital raising earnings report EPS miss public offering
Read the full article at Seeking Alpha
Part of the story Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates (8 articles)